Objective To explore the effect of two methods on phlebitis induced by peripherally intravenously infused dopamine. Methods One hundred and ninety-five patients with phlebitis caused by peripherally intravenously infused dopamine were randomly divided into experiment group and control group according to the parity of hospitalization number in our department during September 2013 to December 2014. Ninety-eighty cases were assigned in the experiment group and 97 in the control group. In the control group, the venous infusion was done with 24G common intravenous detaining needle and general micro pump infusion extension tube. In the experiment group, it was done with 24G safety intravenous detaining needle, disposable connecting pipe with precision filter and DuoDERM attached to the needle wing of puncture site and its upper skin. The two groups were compared in terms of the incidence and occurrence time of phlebitis. Results The incidence of phlebitis in the experiment group was significantly lower than that of the control group, and its severity significantly lower than that of the control group. In addition, the occurrence time was significantly longer than that in the control group. Conclusion Venous infusing with 24G safety intravenous detaining needle, disposable connecting pipe with precision filter, and DuoDERM attached to the needle wing of puncture site and its upper skin can effectively reduce the incidence and occurrence time of phlebitis caused by dopamine.

Adenocarcinoma ; pathology ; Carcinoma, Small Cell ; pathology ; Carcinoma, Squamous Cell ; pathology ; Diagnosis, Differential ; Humans ; Lung Neoplasms ; classification ; genetics ; pathology ; World Health Organization

Bile Duct Neoplasms ; etiology ; pathology ; Bile Ducts, Intrahepatic ; pathology ; Carcinoma in Situ ; etiology ; pathology ; Carcinoma, Papillary ; pathology ; Cholangitis, Sclerosing ; complications ; Diagnosis, Differential ; Humans ; Precancerous Conditions ; etiology ; pathology

Electric Stimulation ; Humans ; Hypoglossal Nerve ; Sleep Apnea, Obstructive ; therapy

Atherosclerosis ; Endothelial Cells ; Humans ; Nitric Oxide Synthase Type III ; Stem Cells

Biomarkers, Tumor ; metabolism ; Hemangioendothelioma, Epithelioid ; metabolism ; pathology ; Hemangiosarcoma ; metabolism ; pathology ; Humans ; Immunohistochemistry ; Leiomyosarcoma ; metabolism ; pathology ; Lung Neoplasms ; metabolism ; pathology ; Nerve Sheath Neoplasms ; metabolism ; pathology ; Pulmonary Blastoma ; metabolism ; pathology ; Sarcoma ; metabolism ; pathology ; Sarcoma, Synovial ; metabolism ; pathology ; Solitary Fibrous Tumors ; metabolism ; pathology

CA-19-9 Antigen ; metabolism ; Carcinoembryonic Antigen ; metabolism ; Carcinoma ; pathology ; Carcinoma in Situ ; etiology ; genetics ; metabolism ; pathology ; Chromosomes, Human, Pair 17 ; Chromosomes, Human, Pair 5 ; Diagnosis, Differential ; Gallbladder Diseases ; pathology ; Gallbladder Neoplasms ; etiology ; genetics ; metabolism ; pathology ; Humans ; Loss of Heterozygosity ; Microsatellite Instability ; Polyps ; pathology ; Precancerous Conditions ; etiology ; genetics ; metabolism ; pathology

Actins ; metabolism ; Adult ; Breast ; pathology ; Breast Neoplasms ; metabolism ; pathology ; surgery ; Female ; Humans ; Mammography ; Neoplasms, Muscle Tissue ; metabolism ; pathology ; surgery ; Vimentin ; metabolism

Adenomatous Polyposis Coli ; genetics ; pathology ; Colonic Neoplasms ; classification ; genetics ; pathology ; Colorectal Neoplasms, Hereditary Nonpolyposis ; diagnosis ; genetics ; DNA Glycosylases ; metabolism ; Humans ; Intestinal Polyps ; pathology ; Lymphatic Metastasis ; Neoplasm Staging ; Neuroendocrine Tumors ; classification ; pathology ; Precancerous Conditions ; pathology ; Rectal Neoplasms ; classification ; genetics ; pathology ; World Health Organization

Objective: To study the expression of function-unknown PNMA5 gene in hepatocellular carcinoma (HCC) and its relationship with proliferation of HCC. Methods: PNMA5 was over-expressed in HCC analyzed by gene expression profiling. We investigated the expression of PNMA5 through RT-PCR and real-time fluorescent quantitative PCR (RFQ-PCR) in normal liver tissues, HCC, and adjacent non-cancerous liver tissues (non-HCC). PNMA5 gene was silenced in Focus and PLC liver cancer cells by using RNA interference technology. The changes in cell growth curve were quantitatively analyzed by performing CCK-8 experiment after silencing the endogenous PNMA5 gene expression. Results: PNMA5 was mainly expressed in testis, ovary, and brain tissues out of the 14 kinds of normal human tissues. PNMA5 mRNA was significantly up-regulated in 42% (5/12) HCC specimens, which was 2-fold higher than that in non-HCCs (P < 0.05). Interestingly, the growth of Focus and PLC cells was markedly inhibited after silencing PNMA5 gene expression (P < 0.01), and the number of tumor cells progressing through G1 and entering S phase was significantly decreased as compared with the control cells transfected with siRNA-NC (P < 0.01). Conclusion: PNMA5 plays an important role in maintaining the malignant phenotype of HCC. It may be a novel tumor-testis associated gene. Further investigation of its function may help to find the new mechanism for the HCC tumorigenesis. PNMA5 may become a new candidate target in HCC treatment.